Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a medical technology company focused on peripheral nerve repair, regeneration, and restoration of function. The AXGN news feed on this page aggregates company announcements, earnings releases, regulatory updates, and other disclosures related to its nerve repair portfolio and corporate activities.
Recent Axogen news has highlighted revenue growth, gross margin trends, and updated financial guidance, as well as developments in reimbursement coverage for nerve repair procedures using allografts and synthetic conduits. Earnings releases and accompanying conference calls provide details on revenue by quarter, profitability metrics, cash and investment balances, and management’s commentary on market development and commercial execution across extremities, oral and maxillofacial, head and neck, and breast reconstruction markets.
Regulatory milestones are a key theme in AXGN news. The company has reported FDA acceptance and subsequent approval of its Biologics License Application for Avance (acellular nerve allograft-arwx), including information on the Prescription Drug User Fee Act (PDUFA) review timeline, accelerated approval indications, and anticipated commercial availability under the biologic framework. Updates on professional society position statements and clinical practice guidelines recognizing nerve allograft as a standard medical practice option for peripheral nerve defects also appear in company communications.
Investors and observers can also find notices about Axogen’s participation in healthcare and investor conferences, where management presents the company’s strategy and meets with institutional investors. By following AXGN news here, readers can monitor financial results, regulatory progress, reimbursement developments, and corporate events that shape Axogen’s peripheral nerve repair business over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, announced plans to release its first quarter 2023 financial results on May 9, 2023, before market opening. Management will conduct a conference call at 8:00 a.m. ET to discuss the results, which investors can join via phone or online. Axogen specializes in technologies for nerve regeneration and repair, with a portfolio that includes products like Avance® Nerve Graft and Axoguard Nerve Connector®. These products are designed to restore nerve function and improve patient quality of life. Axogen's innovations are available in multiple countries, demonstrating its international reach and commitment to patient care.
Axogen reported Q4 2022 revenue of $36.2 million, marking a 17% increase compared to Q4 2021. The company logged a net loss of $5.4 million or $0.13 per share, consistent with the previous year. Adjusted net loss improved to $1.1 million from $3.3 million. The full-year revenue reached $138.6 million, up 12% from 2021. The company anticipates 2023 revenue between $154 million and $159 million. Axogen faced challenges with cash management due to $8 million held at Silicon Valley Bank, which became accessible after the FDIC intervention on March 13, 2023.
Axogen, Inc. (NASDAQ: AXGN) announced the appointment of Marc Began as Executive Vice President and General Counsel, effective March 20, 2023, replacing Brad Ottinger. Began brings over 20 years of legal experience from companies like Abiomed and Novo Nordisk. He will oversee legal and compliance activities under the leadership of Karen Zaderej, Chairman and CEO. Additionally, the company reported inducement grants under NASDAQ listing rules, awarding stock options and restricted stock units to both Began and Chief Marketing Officer Jens Schroeder Kemp. These grants include stock options for 90,000 shares for Began, with an exercise price of $8.16.
Axogen (AXGN) has announced it will release its fourth quarter 2022 financial results on March 14, 2023, before market opening. The company specializes in surgical solutions for peripheral nerve injuries and will host a conference call and webcast at 8:00 a.m. ET on the same day. Investors can participate via phone or listen online through the Axogen website. The company emphasizes its commitment to offering innovative, clinically proven solutions to aid in peripheral nerve repair, with a diverse product portfolio available in multiple countries.
Axogen, Inc. (NASDAQ: AXGN) announced the appointment of Jens Schroeder Kemp as Chief Marketing Officer on February 13, 2023. With over 20 years of experience in medical technology, Kemp will lead the company's marketing strategies and report to Karen Zaderej, Chairman and CEO. His previous role was Vice President of Marketing at Ambu Inc., where he significantly contributed to the single-use endoscopy market. The company aims to leverage Kemp's experience to enhance surgeon adoption and drive innovation in its nerve repair solutions, which include products like Avance Nerve Graft and Axoguard.